Abstract
Pain control measures in sickle cell diseases are not uniform. Most clinicians use parenteral morphine or meperidine for severe pain. Reports of seizures associated with meperidine have led to a growing reliance on intravenous morphine, usually with patient-controlled devices. Acceptance of morphine has been poor among patients, and many prefer meperidine. The aim of this retrospective study was to determine the incidence of meperidine- associated seizures in a large, mostly pediatric population with sickling disorders. The results suggest that the incidence of seizures with meperidine is extremely small (0.4% of patients; 0.06% of admissions). The risk of seizures should not dissuade clinicians from using this drug.
Original language | English |
---|---|
Pages (from-to) | 459-462 |
Number of pages | 4 |
Journal | Clinical Pediatrics |
Volume | 38 |
Issue number | 8 |
DOIs | |
State | Published - 1999 |